# Paolo Zocca

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8486496/publications.pdf

Version: 2024-02-01

| 25 | 659 | 933447 | 580821 |
|---|---|---|---|
| papers | citations | 10 | 25 |
| | | h-index | g-index |

| 25 | 25 | 25 | 979 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet, The, 2016, 388, 2607-2617. | 13.7 | 208 |
| 2 | Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobaltâ€“chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet, The, 2018, 392, 1235-1245. | 13.7 | 112 |
| 3 | Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels. JAMA Cardiology, 2019, 4, 659. | 6.1 | 56 |
| 4 | Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2019, 12, 1650-1660. | 2.9 | 44 |
| 5 | Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention, 2017, 13, 1168-1176. | 3.2 | 42 |
| 6 | 5-Year Outcome Following RandomizedÂTreatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents. JACC: Cardiovascular Interventions, 2018, 11, 462-469. | 2.9 | 41 |
| 7 | Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years. JACC: Cardiovascular Interventions, 2020, 13, 1100-1109. | 2.9 | 26 |
| 8 | â€œSilentâ€•Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 448-459. | 2.9 | 22 |
| 9 | High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. International Journal of Cardiology, 2018, 268, 11-17. | 1.7 | 19 |
| 10 | Three contemporary thinâ€strut drugâ€eluting stents implanted in severely calcified coronary lesions of participants in a randomized allâ€comers trial. Catheterization and Cardiovascular Interventions, 2020, 96, E508-E515. | 1.7 | 12 |
| 11 | First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial. Circulation Journal, 2021, 85, 1983-1990. | 1.6 | 11 |
| 12 | Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. Cardiovascular Diabetology, 2021, 20, 217. | 6.8 | 11 |
| 13 | Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial. American Heart Journal, 2018, 198, 25-32. | 2.7 | 8 |
| 14 | Threeâ€year clinical outcome in allâ€comers with â€œsilentâ€•diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drugâ€eluting stents: From the BIOâ€RESORT Silent Diabetes study. Catheterization and Cardiovascular Interventions, 2020, 96, E110-E118. | 1.7 | 8 |
| 15 | High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. Cardiovascular Drugs and Therapy, 2018, 32, 567-576. | 2.6 | 7 |
| 16 | Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial. Catheterization and Cardiovascular Interventions, 2021, 98, E188-E196. | 1.7 | 6 |
| 17 | Longâ€Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newerâ€Generation Drugâ€Eluting Stents. Journal of the American Heart Association, 2018, 7, . | 3.7 | 5 |
| 18 | Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. International Journal of Cardiology, 2021, 325, 37-44. | 1.7 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents. Current Opinion in Cardiology, 2020, 35, 705-711. | 1.8 | 4 |
| 20 | New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials. American Heart Journal, 2020, 228, 109-115. | 2.7 | 3 |
| 21 | Proximal LAD Treated With Thin-Strut New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 808-816. | 2.9 | 3 |
| 22 | Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial. Coronary Artery Disease, 2021, 32, 51-57. | 0.7 | 2 |
| 23 | Prediction of All-Cause Mortality Following Percutaneous Coronary Intervention in Bifurcation Lesions Using Machine Learning Algorithms. Journal of Personalized Medicine, 2022, 12, 990. | 2.5 | 2 |
| 24 | Serial assessment of endothelial function 1, 6, and 12Âmonths after ST-elevation myocardial infarction. Heart and Vessels, 2018, 33, 978-985. | 1.2 | 1 |
| 25 | Late clinical outcome of stent trials: a matter of life or death?. Lancet, The, 2018, 392, 713-714. | 13.7 | 1 |